8-K: Acrivon Therapeutics Reports Positive ACR-368 Data and First Quarter 2025 Financial Results

Acrivon Therapeutics announces positive clinical data for ACR-368 in endometrial cancer and reports its first quarter 2025 financial results, highlighting a net loss of $19.7 million and a cash balance of $164.8 million.

Summary

• Acrivon Therapeutics reported its first quarter 2025 financial results and provided business updates.
• The company highlighted positive ACR-368 data in endometrial cancer patients, showing a confirmed overall response rate (cORR) of 35% and a median duration of response (mDOR) greater than 5.6 months in OncoSignature-positive (BM+) patients.
• For BM+ patients who had relapsed on their last prior therapy, the cORR was 50% and mDOR was greater than 10 months.
• In the ACR-2316 Phase 1 trial, tumor shrinkage was observed at dose level 3.
• Mansoor Raza Mirza, M.D., was appointed as chief medical officer.
• The company's cash, cash equivalents, and marketable securities totaled $164.8 million as of March 31, 2025, expected to fund operations into the second quarter of 2027.
• The net loss for the quarter ended March 31, 2025, was $19.7 million, compared to a net loss of $16.5 million for the same period in 2024.
• Research and development expenses were $15.4 million, compared to $11.5 million in the same period of 2024.
• General and administrative expenses were $6.2 million, consistent with the same period in 2024.

Sentiment

Score: 8

Explanation: The document presents positive clinical data, a strong cash position, and a strategic appointment, indicating a positive outlook for the company. However, the increased net loss and R&D expenses temper the overall sentiment.

Positives

• Positive clinical data for ACR-368 in endometrial cancer patients, with promising response rates and duration of response.
• Initial clinical activity observed with ACR-2316, including tumor shrinkage at dose level 3.
• Appointment of Mansoor Raza Mirza, M.D., as chief medical officer.
• Strong cash position of $164.8 million, expected to fund operations into the second quarter of 2027.
• Advancement of ACR-2316 to DL4 in the Phase 1 monotherapy clinical trial.

Negatives

• Net loss for the quarter ended March 31, 2025, was $19.7 million, higher than the $16.5 million loss for the same period in 2024.
• Increased research and development expenses, primarily due to the execution of clinical trials for ACR-368 and ACR-2316.

Risks

• The company's future results are subject to risks and uncertainties described in its filings with the Securities and Exchange Commission.
• The forward-looking statements are based on current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict.

Future Outlook

The company expects its cash balance to fund operating expenses and capital expenditure requirements into the second quarter of 2027. Acrivon anticipates providing an update on the registrational-intent trial and confirmatory trial design for ACR-368, reporting initial clinical data from the Phase 1 clinical study of ACR-2316 in the second half of 2025, and advancing a new potential first-in-class cell cycle drug discovery program towards development candidate nomination in 2025.

Management Comments

• We made substantial progress in the first quarter in the advancement of our clinical pipeline and the expansion of our Generative Phosphoproteomics AP3 capabilities, as well as strengthening the executive team, said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.
• With a significant unmet need for second-line treatment options and the potential for label expansion through a confirmatory trial in the front-line setting with ACR-368 used as switch maintenance, we remain very excited by the opportunities for this program.
• For our second clinical-stage asset, ACR-2316, we have observed tumor shrinkage (~25%) in a patient with significant metastatic solid tumor burden after only six weeks of treatment at dose level 3 well before reaching our projected RP2D, supporting its potential for monotherapy activity.
• Finally, we are thrilled and feel privileged that Dr. Mansoor Raza Mirza, a globally recognized oncologist, is now leading the development of our pipeline as CMO.

Industry Context

Acrivon is operating in the competitive precision oncology market, leveraging its proprietary Generative Phosphoproteomics AP3 platform to develop differentiated compounds. The company's focus on endometrial cancer with ACR-368 addresses a significant unmet need, particularly in patients who have progressed after prior platinum-based chemotherapy and anti-PD-1 treatment. The development of ACR-2316, a WEE1/PKMYT1 inhibitor, positions Acrivon in the cell cycle inhibitor space, which is gaining traction in cancer therapy.

Comparison to Industry Standards

• The confirmed overall response rate (cORR) of 35% observed with ACR-368 in OncoSignature-positive endometrial cancer patients is promising compared to historical response rates with standard chemotherapy in similar patient populations.
• For instance, studies evaluating chemotherapy in second-line endometrial cancer have reported response rates ranging from 10% to 20%.
• The median duration of response (mDOR) exceeding 5.6 months with ACR-368 also suggests a potential improvement over existing treatment options.
• The observation of tumor shrinkage with ACR-2316 at dose level 3 in the Phase 1 trial is encouraging, as it indicates potential single-agent activity, which is a key differentiator for WEE1 inhibitors.
• Companies like Zentalis Pharmaceuticals and Turning Point Therapeutics, where Adam D. Levy previously held finance and strategy leadership roles, are also focused on developing targeted cancer therapies, indicating a broader trend in the industry towards precision medicine.

Management Changes

Stakeholder Impact

• Shareholders: Positive clinical data and strong cash position may positively impact shareholder value.
• Employees: Strengthening of the executive team and advancement of clinical programs may improve employee morale and job security.
• Patients: Promising clinical data for ACR-368 and ACR-2316 may offer new treatment options for endometrial cancer and other cancers.

Next Steps

• Provide update on registrational-intent trial and confirmatory trial design for ACR-368.
• Report initial clinical data from the Phase 1 clinical study of ACR-2316 in the second half of 2025.
• Advance a new potential first-in-class cell cycle drug discovery program for an undisclosed target towards development candidate nomination in 2025.

Key Dates

Keywords

Acrivon Therapeutics, ACR-368, ACR-2316, Endometrial Cancer, Financial Results, Clinical Trial, Generative Phosphoproteomics AP3, Oncology, Biotechnology